Ocugen to Host Fireside Chat at Major Investment Conference
Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company specializing in gene and cell therapies, has some exciting news! The CEO and Co-Founder, Dr. Shankar Musunuri, will take part in an important fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference.
Fireside Chat Event Details
This event will be held in the lively backdrop of New York City from September 9-11. During this time, Dr. Musunuri will share insights into Ocugen’s recent accomplishments and outline the company's vision for future innovations.
Engaging with the Investment Community
As Dr. Musunuri puts it: “The H.C. Wainwright Global Investment Conference provides an excellent forum to engage with the investment community.” He is eager to highlight the significant corporate milestones Ocugen has achieved. This event offers a valuable opportunity for the company to communicate its vision and progress directly to investors.
One-on-One Meetings with Executives
In addition to the fireside chat, members of Ocugen's executive team will hold personalized one-on-one meetings with registered investors. These discussions are designed to showcase the company’s innovative business strategies and clinical development initiatives, with a particular focus on their proprietary modifier gene therapy platform, which shows great potential for addressing a range of medical conditions.
Webcast Viewing and Overview
The fireside chat is scheduled for Monday, September 9, at 1:30 p.m. ET, taking place at the Lotte New York Palace Hotel. Those interested can watch a live video webcast on Ocugen’s investor site, allowing a wider audience to participate in the event, which will also be archived for 90 days for later viewing.
About Ocugen, Inc.
Ocugen, Inc. is a beacon of hope in the biotechnology sector, committed to exploring, developing, and commercializing unique gene and cell therapies, along with innovative vaccines aimed at improving health outcomes worldwide. Their dedication to innovation is clear through their pioneering research focused on tackling significant public health challenges.
Research and Impact on Health
With a commitment to addressing unmet medical needs, Ocugen is making significant progress in various fields, including treatments for retinal diseases and infectious conditions. Their forward-thinking approach not only seeks to enhance scientific understanding but also aims to make a meaningful difference in the lives of patients around the globe.
Contact Information
For more information, Tiffany Hamilton, Ocugen's Head of Communications, can be contacted via email at IR@ocugen.com. Stay connected with Ocugen to follow their journey in the biotechnology industry and discover how their innovations are set to transform healthcare.
Frequently Asked Questions
What is the purpose of the H.C. Wainwright Conference for Ocugen?
The conference serves as a vital platform for Ocugen to connect with investors and share insights about their projects and innovations.
Who will represent Ocugen at the event?
Dr. Shankar Musunuri, the CEO and Co-Founder of Ocugen, will lead the discussions during the fireside chat.
When is the fireside chat scheduled?
The fireside chat is set for September 9 at 1:30 p.m. ET.
How can individuals watch the fireside chat?
A live video webcast will be available on Ocugen’s investor site.
What areas does Ocugen focus on in its research?
Ocugen specializes in gene and cell therapies, particularly targeting retinal diseases and infectious conditions, with the goal of enhancing health and well-being.
